Quantcast

Latest Genentech Stories

2014-09-29 16:23:53

In the news release, The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023, issued 18-Sep-2014 by Decision Resources Group over PR Newswire, we are advised by the company that the headline should read $3.8 billion rather than $3.8 million as originally issued inadvertently. The complete, corrected release follows: The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 billion...

2014-09-29 00:21:23

BASEL, Switzerland, Sept. 29, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) today announced that Roche's wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of InterMune, Inc. at USD 74.00 per share in cash. The tender offer expired at 12:00 midnight, New York City time, at the end of the day on 26 September 2014,...

2014-09-18 12:29:19

Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that Regeneron's Eylea, the most recently launched anti-vascular endothelial growth factor (VEGF) agent for wet AMD, is equally likely to be covered on commercial and Medicare Advantage plans as Genentech's Lucentis, which is the standard of care...

2014-09-18 12:27:44

Several Emerging Therapies Will Expand Treatment Armamentarium for Unresectable Locally Advanced or Metastatic Gastric Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that the gastric cancer market will grow exponentially from over $1.1 billion in 2013 to nearly $3.8 billion by 2023. Fuelling this growth will be the launch of five targeted therapies for unresectable locally advanced and metastatic...

2014-09-18 08:30:07

DUBLIN and MELBOURNE, Australia, Sept. 18, 2014 /PRNewswire/ -- Veterinary biologic therapy developer Nexvet Biopharma today announced the appointments of Dr. Ashraf Hanna, M.D., Ph.D., and Dr. Joseph McCracken D.V.M., M.S., to its Board of Directors. Dr. Hanna is the Vice President of Commercial and Medical Affairs Finance at Genentech and Chief Financial Officer for the Genentech Foundation, while Dr. McCracken most recently served as Vice President and Global Head of Business...

2014-09-10 20:24:50

LONDON, Sept. 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Market 2014-2024https://www.reportbuyer.com/product/2006103/Macular-Degeneration-AMD-and-Other-Retinal-Diseases-World-Drug-Market-2014-2024.html Report DetailsAnalysis of revenues and R&D prospects for those eye drugs - you explore potentialsWhat's the future for treating disorders of the retina? Visiongain's updated...

2014-09-03 12:32:05

- Calico to create a leading R&D facility in the San Francisco Bay Area focused on aging and age-related diseases, including neurodegeneration and cancer NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Sept. 3, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Calico announced a novel R&D collaboration intended to help the two companies discover, develop and bring to market new therapies for patients with age-related diseases, including for neurodegeneration and cancer. Calico is the...

2014-08-24 12:20:28

-- Roche to acquire InterMune for $74.00 per share -- BASEL, Switzerland, Aug. 24, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) today announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction. This corresponds to a total transaction value of $8.3 billion on a fully diluted basis. This offer represents a premium of 38% to InterMune's...

2014-08-20 23:05:37

Top Healthcare Talent, Companies and Brand Champions to be Honored September 18th New York, NY (PRWEB) August 20, 2014 The finalists are in for the sixth-annual PM360 Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, will honor the pharmaceutical industry’s most influential innovators. Established in 2009, the Trailblazer Awards are given to outstanding companies, marketers and brand managers representing the best the industry has to offer. “We are proud...

2014-08-18 16:27:51

SUNNYVALE, Calif., Aug. 18, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has appointed Shawn Cline Tomasello as its Chief Commercial Officer. Ms. Cline Tomasello is a 30-year industry veteran and former President of the Americas, Hematology and Oncology, for the Celgene Corporation, where she managed over $4 billion in revenue. Prior to joining Celgene, Ms. Cline Tomasello was the National Director of Hematology for Rituxan(® )at Genentech, where...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related